Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

November 1, 2012

Botulinum toxin with unique makeup compares to market leader

As the popularity of botulinum toxins for both cosmetic and therapeutic applications continues to grow, so too does development of new techniques and formulations. IncobotulinumtoxinA (Xeomin, Merz), the newest of the toxin formulations, is a promising product that according to clinical studies exhibits similar efficacy to onabotulinumtoxinA (Botox, Allergan), despite having a distinctly different biological makeup.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!